Mariner, LLC Bio N Tech Se Transaction History

Mariner, LLC

$58.4 Billion
Q4 2024

A detailed history of Mariner, LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Mariner, LLC holds 3,226 shares of BNTX stock, worth $387,152. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,226

Previous 5,170 37.6%

Holding current value

$387,152

Previous $614,000 40.23%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$99.72 - $122.68 $193,855 - $238,489	-1,944 Reduced 37.6%	3,226 $367,000
Q3 2024 Nov 13, 2024	SELL	$78.36 - $124.66 $660,653 - $1.05 Million	-8,431 Reduced 61.99%	5,170 $614,000
Q2 2024 Aug 13, 2024	SELL	$80.36 - $102.87 $25,715 - $32,918	-320 Reduced 2.3%	13,601 $1.09 Million
Q1 2024 May 15, 2024	SELL	$88.96 - $112.35 $26,776 - $33,817	-301 Reduced 2.12%	13,921 $1.28 Million
Q4 2023 Feb 14, 2024	BUY	$90.91 - $112.75 $1.05 Million - $1.3 Million	11,553 Added 432.86%	14,222 $1.5 Million
Q3 2023 Nov 13, 2023	BUY	$98.5 - $125.08 $262,896 - $333,838	2,669 New	2,669 $289,000

Others Institutions Holding BNTX

# of Institutions

363

Shares Held

39.6M

Call Options Held

3.01M

Put Options Held

2.01M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $29.1B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Account